NEWS & EVENTS | OSLO UNIVERSITETSSYKEHUS - HOSPITAL PAGES IN NORWEGIAN

Gustav

Gaudernack

 

CV

Education: Cand.real (PhD equivalent) in biochemistry, University of Oslo, 1972

 

Positions: Professor in immunotherapy, The Faculty of Medicine, University of Oslo 2007-.  Head of Department of Immunology, Rikshospitalet-Radiumhospitalet Medical Center/University Hospital 2007- 2008. Guest Professor in Immunotherapy, Medical Faculty, University of Bern, Switzerland, 2000-2007. Head, Section for Immunotherapy, Institute of Cancer Research, Rikshospitalet-Radiumhospitalet Medical Center 1995- present. Senior Scientist, The Norwegian Cancer Society, Institute of Transplantation Immunology, The National Hospital, University of Oslo 1986-1995. Research fellow, The Norwegian Cancer Society, Institute of Transplantation Immunology, The National Hospital, University of Oslo,1983-1986. Research fellow, The Norwegian Cancer Society, University of Tromsø, 1979-1983. Research fellow (Arthritis Foundation), University of Minnesota, Minneapolis,USA, 1980-1981. Research fellow, Department of Immunology, University of Tromsø, 1973-1979. Visiting fellow, Department of Biochemistry, University of Tromsø, 1972.

 

 

Research experience:  Main areas of research have been (in chronological order): Trombosis and haemostasis, including coagulation and monoclonal antibodies against receptors on blood platelets and coagulation factors. Experimental cancer research in murine model systems, involving anti-idiotypic antibodies for therapy of B-cell tumours, and the role of NK-cells and macrophages in tumour immunology. Production of monoclonal antibodies against human cancer cells and cells of the immune system. Production of monoclonal antibodies against HLA molecules for the study of the role of these molecules in peptide specificity, T cell recognition, tumour immunology and transplantation. Mechanisms of host-tumour recognition; Studies on the function of HLA molecules, T cell subsets and antigen presenting accessory cells in tumour immunology and transplant rejection processes. Production of monoclonal antibodies against haematopoetic progenitor cells for leukaemia phenotyping, studies of early haematopoiesis and as tools in gene therapy directed at haematopoetic progenitor cells. Development of new methods for isolation of pure cell subsets including haemopoietic stem cells by magnetic immunobead technology. Clinical cancer immunology, including studies of the immune system in various groups of cancer patients. Specific immunotherapy; Development of cancer vaccines targeting mutant oncogenes, including RAS, TGFβRII and other oncogenes/tumor suppressor genes, and characterization of the HLA molecules and T cells involved in oncopeptide responses. Translational research: Clinical trials; testing of vaccine candidates in phase I/phase II clinical trials. Gene therapy/immuno-gene therapy, including cancer vaccines based on engineered dendritic cells transfected with tumour mRNA and reprogrammed using cytokine mRNA and siRNA for gene silencing and re-directed T cells engineered by transfection of mRNA encoding chimeric receptors and selected T cell receptors. Immunogenomics: High througput technologies for tumor antigen discovery, including SEREX and fully automated SEREX with filamentous phage tumor cDNA expression libraries.  Carcinogenesis and molecular pathology, including genetics and epigenetics of colorectal cancer. Immunogenetics/pharmacogenetics: Role of SNP's and other polymorphisms in determining immune responses to cancer vaccines and in tumor development. Development of immunotherapy targeting  cancer stem cells. Targeting of nanoparticles to micrometastasis and cancer stem cells.

 

Scientific highlights: Generation of a large panel of reference monoclonal antibodies against haematopoietic stem cells (1987). First detection of spontaneous immune responses in cancer patients against point mutation in ras oncogene (Int. Immunol. 1992). First publication of a clinical trial (first in man) of a peptide vaccine in cancer patients (The Lancet 1995). Comprehensive model of Carcinogenesis and natural selection (Adv. Cancer Res. 1999). First detection of spontaneous responses against a new class of frameshift mutations in colon cancer patients (PNAS 2001), opening for prophylactic vaccines for patients with genetical risk of colorectal cancer. First in man trial of mutant K-ras peptide vaccines in patients with malignant melanoma (Experimental Dermatol. 2001). Initiated first hTERT peptide vaccine trial in man (2000). First telomerase peptide trial in patients with lung cancer (Cancer Immunol. Immunother 2006). First telomerase peptide trial in patients with pancreatic adenocarcinoma (Br. J. Cancer 2006).  First immuno gene therapy trials using mRNA transfected DC's in patients with malignant melanoma and prostate cancer (Br. J. Cancer 2005 and Cancer Immunol Immunother 2006).


Teaching experience: One-year course in biochemistry for lab. technicians. Courses in general immunology and immunological techniques for dental students, medical students, Ph.D students and postdoctoral training for MD's. Supervisor for three MD research students (studentstipendiat) and twentytwo Ph.D students in transplantation immunology and experimental and clinical cancer immunology, currently five Ph.D. students.


Administrative experience (University): Member of the council and board of the Institute of Medical Biology, The University of Tromsø. Member of the council and board of the Institute group of Laboratory Medicine, The National Hospital, University of Oslo. Head of the monoclonal antibody group and laboratory, Institute of Transplantation Immunology from 1983-1994. Head of cancer vaccine research group (Institute of transplantation Immunology) 1990-1994.

Head of Section for Immunotherapy (The Norwegian Radium Hospital) since 1995 (currently 12 person staff).

Head Department of Immunology (Radiumhospitalet, Rikshospitalet Medical Center) 2007-2008 (currently 45 person staff).

 

Commitees and advisory boards:

 

University: Member of Strategy Committee (The National Hospital, until 1995) and Patent advisory Board (The Norwegian Radium Hospital). Presently: Steering Committee for Immunotherapy (The Norwegian Radium Hospital), Steering Committee for Gene Therapy (The Norwegian Radium Hospital), Board of Oncology Forum, Board of Inger and John Fredriksen Foundation for Ovarian Cancer Research.

External: Member of the EORTC biological trials development group (BTDG) and the International Cooperative Group on Hereditary Non Polyposis Cancer (ICG-HNPCC). Member Advisory Board, Biological Therapy of Cancer-From Disease to Target-oriented Therapy (EORTC/NCI), and Scientific Committee International Society for Cancer Gene Therapy (Singapore Meeting). Member of Advisory Board on Peptide Vaccine Approaches, Merck KGaA (until 2001), Advisory Board Centocor GenVax program, Advisory Board DYNAL Biotec: Immunosystems, Advicory Board on Multipheron-Swedish Orphan, Board member Diatec AS. Technical advisory Board Pharmexa AS, Chairman Advisory Board GemVax AS, Member Advisory board KAEL-GemVax, Advisory Board Lytix, Advicory Board Fresenius Biotech, Member Scientific Panel for Biotherapy Development Association (BDA), Member ISHAGE Immunotherapy & Dendritic Cells Committee. Member External Reviewer Panel, Cancer Research Campaign (CRC, UK) vaccine protocols. Member international technical evaluator panel for Advanced Technologies Research Programme 2001 (Enterprise Irland/BioResearch Irland).

 

Grant reviewing: National Science Foundation (USA); Grant on industrial applications of enzymes conjugated to magnetic support. International Human Frontier Science Program (Strasbourg); Several projects in the field of tumor immunology. Danish Cancer Society (Copenhagen, Denmark); Tumor Immunology and vaccine development project. Dutch Cancer Society (Nederlandse Kankerbestrijding); Prophylactic vaccination in women at high risk of breast/ovarian cancer. Clinical and translational cancer research grants, Cancerföreningen i Stockholm/King Gustaf V's Jubileumsfond; Willy Gepts Research Foundation (Brussels); The Norwegian Research Council and The European Commission's: "Combating Cancer Program". German Research Foundation/German Ministerium for Health: Clinical Trials Evaluation Panel and Evaluation Panel Van Geest Cancer Center.



Scientific Journals: Member editorial board Journal of Immunotechnology, Cancer Immunology and Immunotherapy and Bio Med Central (BMC) Cancer. Regular referee for Scandinavian Journal of Immunology, Tissue Antigens, Blood and Medical Oncology. Referee Nature Cancer Reviews and Nature Immunology.

 

Societies: Founding member European Society for Cancer Immunothetapy, member International Society for Biological Therapy of Cancer, International Society for Cancer Gene Therapy, European Federation for Immunogenetics,  BDA Immunotherapy Working Group, Norwegian Biochemical Society and Norwegian Society for Immunology.

 

Doctoral disertations: Elected faculty opponent in doctoral dissertations at the Karolinska Institute (Fil. Dr. Flavio Salazar-Onfrey, Fil. Dr. Simona Vertuani), the University of Uppsala (cand.med. Ole Forsberg), The Technical University of Denmark (Mads Hald Andersen, PhD, dr. techn), København Universitet (Özsan Met PhD and Lynn Wenandi PhD) and at the Medical Faculty, University in Oslo (dr. med. Grete F. Lauritsen, dr. med. Øivind Molberg, dr.phil. Karoline Western Schjetne, dr.med. Trygve Holmøy, dr. med. Katrin Lundin, dr.med Jacob Dalgaard, dr.med Sheraz Yaqub, dr.med and Line Mari Flornes)

 

Invited speaker, scientific meetings (2000-2010): UICC Expert Meeting on Clinical Trials with Dendritic Cells (Zürich 2000), Baltic Summer School 2000: Current Trends in Immunology (Kiel 2000), Eurocellpath: Molecular Mechanisms in Development and Treatment of Cancer (Lillehammer 2000), Society for Biological Therapy 1st Int. Meeting (Berlin 2000), ECCO 11: Symposium on Cancer Vaccines (Lisboa 2001), First International Adriatic See Symposium on Novel Targets for Cancer Therapy (Trieste 2001), Biological Therapy of Cancer - From Basic Research to Clinical Application (München 2001), 3rd Joint Meeting Leeds Castle Polyposis Group and International Collaboratory Group on HNPCC (Venice 2001), 1st EORTC Translational Research Meeting (Brussels 2001), Progress in Vaccination against Cancer, PIVAC 2001 (Cambridge 2001), Symposium on Genomic Instability and Immunoselection in Cancer Development (Schloss Elmau 2001), 33rd Scandinavian Society for Immunology Meeting (Bergen 2002), 3rd World Congress on Vaccines and Immunization (Opatija 2002), 4th International Dresden Symposium on Immunotherapy of Cancer (Dresden 2002), Progress in Vaccines Against Cancer (Nottingham 2002), 8th Annual Meeting International Society for Cellular Therapy (Barcelona 2002), From Tumor Immunology to Immune and Gene Therapy of Cancer (Stockholm 2002), Nordic Workshop on Immunotherapy of Cancer (Sockholm 2002), 34th Scandinavian Society for Immunology Meeting (Reykjavik 2003),  4th International Symposium on Minimal Residual Cancer (Oslo 2003), Dendritic Cell therapy; Fact or Fiction - EBMT Satellite Symposium (Istanbul 2003), Nordic Melanoma Meeting (Visby 2003),  International Cancer Vaccine Symposium (Beijing 2003), Finish Society for Pediatric Oncology and Hematology (Helsinki 2004), XXXVI Meeting European Pancreatic club (Padova 2004), EuroScience Open Forum (Stockholm 2004), Cancer Immunology and Immunotherapy Summer School (Ionian Village, Pellopones 2004 ), PIVAC 2004 (Blaubähren 2004), 34th European Society for Dermatology Research Meeting (Wien 2004), XIIth  International Cancer Gene Therapy Meeting (Singapore 2004), Stem Cells and Telomerase: Targets for Transformation and therapeutic applications (Cyprus 2004), 1st International Conference on Basic and Clinical Immunogenomics (Budapest 2004) and Symposium on Immunotherapy of Cancer (Copenhagen 2005), EBMT Annual Meeting (Praha 2005), 13th United European Gastroenterology Week (Copenhagen/Malmö, 2005), PIVAC 2005 (Athens 2005), Genetic control of T cell activation: Implications for autoimmunity and cancer (Lofoten 2005), Molecular Mechanisms in Cancer (Moscow 2005), EFI 20th Immunogenetics and Histocompatibility Conference (Oslo 2006), 31st ESMO Congress (Istanbul 2006), CNIO/Josef Steiner Cancer Conference (Madrid 2006), EORTC-AACR  meeting on Biological therapy of Cancer (Dresden 2006), Anticancer Vaccines: Developing the product to improve efficacy (Forli 2007), Cancer Immunotherapy (Stockholm 2007), Transatlantic Symposium: Advancing Translational Cancer Research and Innovation (N. Carolina 2007), ), AACR Conference: The role of Telomers and Telomerase in Cancer Research (San Fransisco 2007), 10th International Workshop on Langerhans Cells (Bern 2007), 5th International Meeting on Dendritic Cell Vaccination: DC2007 (Bamberg 2007), First International Conference on Cancer Stem Cells (Hangzhou 2007), Oslo-London Cancer Research Symposium (London 2007), BDA-iSBTC Joint Meeting "9th International Symposium of Biological Therapy of Cancer" (München 2008),  European Workshop on Telomeres and Telomerase in Cancer and Ageing (Ladenburg 2008), Tumor Immunology Meets Oncology IV (Halle 2008), Elliott-Nowell-White Symposium (Cleveland 2008), Workshop on "Vaccine Management of Cancer" (Torino 2008),  Eigth Elsinore Meeting on Infection Immunity (København 2009), PIVAC-9 (Sofia 2009), Scientific Symposium on Dendritic Cells (Barcelona 2009), 2nd International conference on cancer stem cells (Zhangzou 2010), PIVAC-10 (Cambridge), EXPO 2010 From Cancer Research to Cure (Shanghai 2010), EACR (Oslo 2010), Beijing Cancer Forum (Beijing 2010)

 

 

Meeting organization: Tromsø Summer School in Experimental Medicine and Biology, 1981. The annual Winter Meeting of the Norwegian Biochemical Society, 1990. 1st Scandinavian Seminar on Cancer Vaccines, The Norwegian Radium Hospital, 1995. Scandinavian Seminar on Tumor Immunology and Immunotherapy, Oslo, 2000. ), Merck Symposium on GM-CSF as adjuvant in cancer vaccines (Oslo 2000), Cellular Immunotherapy,18th UICC-ICC Congress  (Oslo 2002), XIIth  International Cancer Gene Therapy Meeting (Singapore 2004), Cancer Immunology and Immunotherapy Summer School (Ionian Village, Pellopones 2004), NCEV annual meeting (Oslo 2005), PIVAC 2005 (Athens), Cancer Stem cells (Oslo 2006), PIVAC 2006 (Granada) and EORTC-AACR  meeting on Biological therapy of Cancer (Dresden 2006), EACR Workshop on translational cancer research (Oslo 2010)

 

Workshop participation: Submitted a number of own monoclonal antibodies to and actively participated in several of the International Workshops on Human Leucocyte Differentiation Antigens and the International Histocompatibility Workshops. Several of these antibodies are now reference CD antibodies or HLA reagents.


Clinical trials: Organization of and participation in more than twenty-five investigator initiated clinical trials of tumor vaccines and immuno-gene therapy. These trials include the first study of a ras peptide vaccine (1993) and the first study of telomerase peptide vaccination in cancer patients (2000), seven immuno-gene therapy trials with mRNA transfected dendritic cells.


Scientific cooperation: Member of CEVI (center for vaccine development and immunotherapy, Medical Faculty, University of Oslo). Recent project cooperation with Affitech AS on the identification on pancreas, prostate and breast cancer antigens by the use of high throughput phage technology. Cooperation with the International Cooperative Group on HNPCC (ICG-HNPCC), Prof. Annika Lindblom, The Karolinska Institute and Prof. Magnus von Knebel Doeberitz at Heidelberg University on development and testing of prophylactic vaccines against HNPCC. Cooperation with National Cancer Research Network UK on Phase III study of telomerase vaccine (TeloVax protocol). Long term research cooperaration with Prof. Rolf Kiessling and others at the Karolinska Institute, Stockholm and Danish Center for Cancer Immunotherapy (CCIT), Herlev Hospital, Copenhagen. Member of Adoptive T Cell Therapy Consortium (ACT). Co-founder and member of Nordic Center of Excellence for Immunotherapy (http://www.cck.ki.se/ncev/). Member of EU projects EUCAPS, ENACT, CIMT, CHILDHOPE and NANOMEDPART (ERA-NET). Associated member of EU project ALLOSTEM. 

 

Awards: Medinnovas Idepris (with Tobias Gedde-Dahl d.y.) 1993 (NOK. 100.000), Medical Faculty Institute of Laboratory Medicine. RH, Strategy Prize (with Bjarne Bogen) 1994 (NOK. 20.000), European Bone Marrow Transplantation Society van Bekkum Award 2005.

 

Research grants, including industrial grants:

National Institutions: Receiving continuous grant support from the Norwegian Cancer Society since 1980. Grants from the Norwegian Research Council (1992-2003) and Medinnova (1992-1995). FUGE/ Affitech ASA (High throughput immunogenomics, 2004-2007), GemVax/Skattefunn (Cancer vaccine development, 2001). Affitech ASA/Norwegian research council (MedKap) (Cancer diagnostics and therapeutics, 2002) and Genovision/ Norwegian Research Council (Automated telomerase assay development 2001-2004). Norwegian Research Council/ERA-Net grant in nanotechnology NANOMEDPART (2007-2009). Norwegian Research Council: Centre for Research based Innovation (CRI) Canser Stem cells (2007-2015). Norwegian Research Council/FUGE (Re-directed T cells, with Johanna Olweus) (2008-2010). Norwegian Research Foundation (Verification grant for early detection of Diabetes and Pancreatic cancer) (2007-2008). Fredriksen Foundation (Development of cancer vaccines against ovarian cancer) (2006).  International Institutions: Arthritis Foundation, USA (1980). EU "Concerted Action" grant for cancer vaccines EUCAPS (1998-2000), "Special Targeted Projects" grant ENACT (2004-2007) and CHILDHOPE grant for developing re-directed T cells for leukemia therapy in pediatric patients (2007-2010). Danish Council for Strategic Research Grant (New strategies for adoptive cell transfer in cancer treatment, 2009-2013).

Industrial Grants: Pronova A/S (Cancer vaccine development, 1990-1995) and HYDRO ASA (Cancer vaccine development, 1995-2002). GemVax (Cancer vaccine development, 2002-2005), Pharmexa (Cancer vaccine development, 2005-2006.

 

Patent applications/patents:   (more than 50 national patents in 10 patent families)

 

1) Through Medinnova:

Gaudernack, G., Gedde-Dahl III, T. and Eriksen, J.A.: Therapeutically usefull peptides or peptide fragments ( Int. Pat. PCT/WO92/14756 AU660452 US0561978 EP529023B1). Patent granted in EU, USA,Canada and Australia.

 

Breivik, J., Spurkland, A. and Gaudernack, G.: DNA fragment condensation (Rapid magnetic isolation of DNA, Int. Pat. Appl. PCT/GB94/02469). Patent granted inNorway, EU, Australia and USA.

 

Breivik, J. and Gaudernack, G.: Mutation Detection ( A sensitive method for detection of point mutations in codon 12 and 13 of K-ras, United Kingdom Pat. Appl. No. 9323305.4, WP Ref.59191.570). Patent granted in Norway, Australia, Europe and USA.

 

Gaudernack, G and Alsøe L: A method for detecting diabetes or pancreatic cancer: UK Patent Application 081080.3.

 

Gaudernack, G, Suso Indreberg, EM and Rasmussen A-M: European Patent application WGA/PN791356EP. Telomerase vaccines. February 2010

 

 

2) Through the Radium Hospital Research Foundation:

Gaudernack, G., Gjertsen, M.K. and Eriksen, J.A.: Peptides (CTL epitopes derived from mutant ras, UK patent appl. PCT/GB97/18110.1 PCTWO00/02581).

 

Gaudernack, G., Gjertsen, M.K., Sæterdal, I.v.M.,  Møller, M. and Eriksen, J.A.: Peptides (A large series of newly defined frameshift peptides as cancer vaccine candidates, Norwegian and international application. PCT/WO99/58552). Patent granted in USA, Australia and Norway.

 

Gaudernack, G., Møller, M. and Eriksen, J.A.: Peptides ( New peptide vaccine candidates for degenerative diseases. Norwegian and international application. PCT/NO99/00141 WO99/58564). Patent granted in USA, Australia and Norway

 

Gaudernack, G. Sæbøe-Larssen, S., Gjertsen, M.K., Sæterdal, I.v.M., Møller, M. and Eriksen J.A.: Antigenic Peptides (Norwegian and international application. PCT/NO99/0020 WO 00/02581, "Antigenic Peptides Derived from Telomerase"). Patent granted in EU, Norway and Australia.

 

Eriksen, J.A., Gaudernack, G, Gjertsen, M.K. and Møller, M.:Peptides (ras peptide cocktails for more efficient vaccination. PCT/NO00/00142 WO99/58564). Patent granted in Norway.

 

Gaudernack, G., Bjørheim, J, Møller, M. and Eriksen, J.A.: Peptides ( New peptide vaccine candidates for Cancer. British Patent Application PCT/NO01/00180)

 

Sæbøe-Larssen, S., Møller, M. and Eriksen J.A. Gaudernack, G.: Telomerase peptides (Telomerase splice variants (s insert) for use in cancer immunotherapy). UK patent application number: PCT/GB0031430.2 WO/99/58564


Sæbøe-Larssen, S., Møller, M. and Eriksen J.A. Gaudernack, G.: Polypeptides  (Telomerase splice variants for use in cancer immunotherapy). Patent application number: PCT/NO99/00141 WO99/58564

 

Gaudernack, G., Møller, M. and Eriksen J.A.: Antigenic Peptides (Norwegian and international application. PCT/GB0105238.0 "hTERT fragment with nested epitopes")

 

Sebøe-Larssen, S and Gaudernack, G.: Genetic Material (Improved method for transfection of dendritic cells. UK patent application number: PCT/NGB0112342.1

 

 

Publications

Publications by Gustav Gaudernack

202 publications found

Publications in press

  1. Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H
    Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab
    Leuk Lymphoma (in press)
    PubMed 23391141

Publications 2013

  1. Wang P, Gao Q, Suo Z, Munthe E, Solberg S, Ma L, Wang M, Westerdaal NA, Kvalheim G, Gaudernack G (2013)
    Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines
    PLoS One, 8 (3), e57020
    PubMed 23469181

Publications 2012

  1. Adamczak M, Hoel HJ, Gaudernack G, Barbasz J, Szczepanowicz K, Warszy?ski P (2012)
    Polyelectrolyte multilayer capsules with quantum dots for biomedical applications
    Colloids Surf B Biointerfaces, 90, 211-6
    PubMed 22078925
  2. Inderberg-Suso EM, Trachsel S, Lislerud K, Rasmussen AM, Gaudernack G (2012)
    Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001
    Oncoimmunology, 1 (5), 670-686
    PubMed 22934259
  3. Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H (2012)
    Polymorphisms in genes encoding interleukin-10 and drug metabolizing enzymes GSTP1, GSTT1, GSTA1 and UGT1A1 influence risk and outcome in Hodgkin lymphoma
    Leuk Lymphoma, 53 (10), 1934-44
    PubMed 22475179

Publications 2011

  1. Almåsbak H, Rian E, Hoel HJ, Pulè M, Wälchli S, Kvalheim G, Gaudernack G, Rasmussen AM (2011)
    Transiently redirected T cells for adoptive transfer
    Cytotherapy, 13 (5), 629-40
    PubMed 21174490
  2. Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S (2011)
    Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial
    Clin Cancer Res, 17 (21), 6847-57
    PubMed 21918169
  3. Hunger RE, Kernland Lang K, Markowski CJ, Trachsel S, Møller M, Eriksen JA, Rasmussen AM, Braathen LR, Gaudernack G (2011)
    Vaccination of patients with cutaneous melanoma with telomerase-specific peptides
    Cancer Immunol Immunother, 60 (11), 1553-64
    PubMed 21681371
  4. Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S (2011)
    Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients
    Clin Cancer Res, 17 (13), 4568-80
    PubMed 21586625
  5. Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G, Gaudernack G (2011)
    hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes
    Cancer Immunol Immunother, 60 (6), 809-18
    PubMed 21365467
  6. Torfoss D, Sandstad B, Mollnes TE, Høiby EA, Holte H, Bjerner J, Bjøro T, Gaudernack G, Kvalheim G, Kvaløy S (2011)
    The mild inflammatory response in febrile neutropenic lymphoma patients with low risk of complications is more pronounced in patients receiving tobramycin once daily compared with three times daily
    Scand J Immunol, 74 (6), 632-9
    PubMed 21883353
  7. Wedén S, Klemp M, Gladhaug IP, Møller M, Eriksen JA, Gaudernack G, Buanes T (2011)
    Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras
    Int J Cancer, 128 (5), 1120-8
    PubMed 20473937

Publications 2010

  1. Abrahamsen IW, Stronen E, Wälchli S, Johansen JN, Kjellevoll S, Kumari S, Komada M, Gaudernack G, Tjonnfjord G, Toebes M, Schumacher TN, Lund-Johansen F, Olweus J (2010)
    Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif
    Leukemia, 24 (11), 1901-9
    PubMed 20844564
  2. Rasmussen AM, Borelli G, Hoel HJ, Lislerud K, Gaudernack G, Kvalheim G, Aarvak T (2010)
    Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy
    J Immunol Methods, 355 (1-2), 52-60
    PubMed 20171968
  3. Szczepanowicz K, Hoel HJ, Szyk-Warszynska L, Biela?ska E, Bouzga AM, Gaudernack G, Simon C, Warszynski P (2010)
    Formation of biocompatible nanocapsules with emulsion core and pegylated shell by polyelectrolyte multilayer adsorption
    Langmuir, 26 (15), 12592-7
    PubMed 20604580

Publications 2009

  1. Copier J, Dalgleish AG, Britten CM, Finke LH, Gaudernack G, Gnjatic S, Kallen K, Kiessling R, Schuessler-Lenz M, Singh H, Talmadge J, Zwierzina H, Håkansson L (2009)
    Improving the efficacy of cancer immunotherapy
    Eur J Cancer, 45 (8), 1424-31
    PubMed 19167214
  2. Gao Q, Geng L, Kvalheim G, Gaudernack G, Suo Z (2009)
    Identification of cancer stem-like side population cells in ovarian cancer cell line OVCAR-3
    Ultrastruct Pathol, 33 (4), 175-81
    PubMed 19728235
  3. Kyte JA, Trachsel S, Risberg B, thor Straten P, Lislerud K, Gaudernack G (2009)
    Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination
    Cancer Immunol Immunother, 58 (10), 1609-26
    PubMed 19221745
  4. Stronen E, Abrahamsen IW, Gaudernack G, Wälchli S, Munthe E, Buus S, Johansen FE, Lund-Johansen F, Olweus J (2009)
    Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells
    Scand J Immunol, 69 (4), 319-28
    PubMed 19284496

Publications 2008

  1. Alsøe L, Stacy JE, Fosså A, Funderud S, Brekke OH, Gaudernack G (2008)
    Identification of prostate cancer antigens by automated high-throughput filter immunoscreening
    J Immunol Methods, 330 (1-2), 12-23
    PubMed 18045611
  2. Kloster MM, Hafte TT, Moltzau LR, Naderi EH, Dahle MK, Skålhegg BS, Gaudernack G, Levy FO, Naderi S, Blomhoff HK (2008)
    EBV infection renders B cells resistant to growth inhibition via adenylyl cyclase
    Cell Signal, 20 (6), 1169-78
    PubMed 18406106

Publications 2007

  1. Jarnjak-Jankovic S, Hammerstad H, Saebøe-Larssen S, Kvalheim G, Gaudernack G (2007)
    A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines
    BMC Cancer, 7, 119
    PubMed 17608923
  2. Jarnjak-Jankovic S, Saebøe-Larssen S, Kvalheim G, Gaudernack G (2007)
    mRNA transfection of DC in the immature or mature state: comparable in vitro priming of Th and cytotoxic T lymphocytes against DC electroporated with tumor cell line-derived mRNA
    Cytotherapy, 9 (6), 587-92
    PubMed 17882723
  3. Kyte JA, Kvalheim G, Lislerud K, thor Straten P, Dueland S, Aamdal S, Gaudernack G (2007)
    T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells
    Cancer Immunol Immunother, 56 (5), 659-75
    PubMed 16947019

Publications 2006

  1. Bernhardt SL, Gjertsen MK, Trachsel S, Møller M, Eriksen JA, Meo M, Buanes T, Gaudernack G (2006)
    Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study
    Br J Cancer, 95 (11), 1474-82
    PubMed 17060934
  2. Brunsvig PF, Aamdal S, Gjertsen MK, Kvalheim G, Markowski-Grimsrud CJ, Sve I, Dyrhaug M, Trachsel S, Møller M, Eriksen JA, Gaudernack G (2006)
    Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer
    Cancer Immunol Immunother, 55 (12), 1553-64
    PubMed 16491401
  3. Gaudernack G (2006)
    Prospects for vaccine therapy for pancreatic cancer
    Best Pract Res Clin Gastroenterol, 20 (2), 299-314
    PubMed 16549329
  4. Kyte JA, Gaudernack G (2006)
    Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells
    Cancer Immunol Immunother, 55 (11), 1432-42
    PubMed 16612595
  5. Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, Gullestad HP, Ryder T, Lislerud K, Hammerstad H, Gaudernack G (2006)
    Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA
    Cancer Gene Ther, 13 (10), 905-18
    PubMed 16710345
  6. Saebøe-Larssen S, Fossberg E, Gaudernack G (2006)
    Characterization of novel alternative splicing sites in human telomerase reverse transcriptase (hTERT): analysis of expression and mutual correlation in mRNA isoforms from normal and tumour tissues
    BMC Mol Biol, 7, 26
    PubMed 16939641

Publications 2005

  1. Jarnjak-Jankovic S, Pettersen RD, Saebøe-Larssen S, Wesenberg F, Gaudernack G (2005)
    Evaluation of dendritic cells loaded with apoptotic cancer cells or expressing tumour mRNA as potential cancer vaccines against leukemia
    BMC Cancer, 5, 20
    PubMed 15720715
  2. Jarnjak-Jankovic S, Pettersen RD, Saebøe-Larssen S, Wesenberg F, Olafsen MR, Gaudernack G (2005)
    Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma
    Cancer Gene Ther, 12 (8), 699-707
    PubMed 15846368
  3. Kyte JA, Kvalheim G, Aamdal S, Saebøe-Larssen S, Gaudernack G (2005)
    Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination
    Cancer Gene Ther, 12 (6), 579-91
    PubMed 15818380
  4. Mu LJ, Kyte JA, Kvalheim G, Aamdal S, Dueland S, Hauser M, Hammerstad H, Waehre H, Raabe N, Gaudernack G (2005)
    Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients
    Br J Cancer, 93 (7), 749-56
    PubMed 16136047

Publications 2004

  1. Breivik J, Gaudernack G (2004)
    Resolving the evolutionary paradox of genetic instability: a cost-benefit analysis of DNA repair in changing environments
    FEBS Lett, 563 (1-3), 7-12
    PubMed 15063714
  2. Fosså A, Alsøe L, Crameri R, Funderud S, Gaudernack G, Smeland EB (2004)
    Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display
    Cancer Immunol Immunother, 53 (5), 431-8
    PubMed 14747957
  3. Fosså A, Berner A, Fosså SD, Hernes E, Gaudernack G, Smeland EB (2004)
    NY-ESO-1 protein expression and humoral immune responses in prostate cancer
    Prostate, 59 (4), 440-7
    PubMed 15065093
  4. Kersten C, Delabie J, Gaudernack G, Smeland EB, Fosså A (2004)
    Analysis of the autoantibody repertoire in Burkitt's lymphoma patients: frequent response against the transcription factor ATF-2
    Cancer Immunol Immunother, 53 (12), 1119-26
    PubMed 15185015
  5. Lazarova P, Lijun M, Hammerstad H, Nesland J, Gaudernack G, Kvalheim G (2004)
    Experimental attempt to introduce a vaccine therapy by using DC-developed from CD34+cells
    NATO SCI SER I LIFE, 361, 134
  6. Mu LJ, Lazarova P, Gaudernack G, Saeboe-Larssen S, Kvalheim G (2004)
    Development of a clinical grade procedure for generation of mRNA transfected dendritic cells from purified frozen CD34(+) blood progenitor cells
    Int J Immunopathol Pharmacol, 17 (3), 255-63
    PubMed 15461859

Publications 2003

  1. Bjorheim J, Minarik M, Gaudernack G, Ekstrom PO (2003)
    Evaluation of denaturing conditions in analysis of DNA variants applied to multi-capillary electrophoresis instruments
    J. Sep. Sci., 26 (12-13), 1163-1168
  2. Bjørheim J, Abrahamsen TW, Kristensen AT, Gaudernack G, Ekstrøm PO (2003)
    Approach to analysis of single nucleotide polymorphisms by automated constant denaturant capillary electrophoresis
    Mutat Res, 526 (1-2), 75-83
    PubMed 12714185
  3. Bjørheim J, Gaudernack G, Giercksky KE, Ekstrøm PO (2003)
    Direct identification of all oncogenic mutants in KRAS exon 1 by cycling temperature capillary electrophoresis
    Electrophoresis, 24 (1-2), 63-9
    PubMed 12652573
  4. Gjertsen MK, Saeterdal I, Saebøe-Larssen S, Gaudernack G (2003)
    HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes
    J Mol Med (Berl), 81 (1), 43-50
    PubMed 12545248
  5. Mu LJ, Gaudernack G, Saebøe-Larssen S, Hammerstad H, Tierens A, Kvalheim G (2003)
    A protocol for generation of clinical grade mRNA-transfected monocyte-derived dendritic cells for cancer vaccines
    Scand J Immunol, 58 (5), 578-86
    PubMed 14629630

Publications 2002

  1. Bjorheim J, Gaudernack G, Ekstrom PO (2002)
    Melting gel techniques in single nucleotide polymorphism and mutation detection: From theory to automation
    J. Sep. Sci., 25 (10-11), 637-647
  2. Bjørheim J, Minarik M, Gaudernack G, Ekstrøm PO (2002)
    Mutation detection in KRAS Exon 1 by constant denaturant capillary electrophoresis in 96 parallel capillaries
    Anal Biochem, 304 (2), 200-5
    PubMed 12009696
  3. Ekstrøm PO, Bjørheim J, Gaudernack G, Giercksky KE (2002)
    Population screening of single-nucleotide polymorphisms exemplified by analysis of 8000 alleles
    J Biomol Screen, 7 (6), 501-6
    PubMed 14599347
  4. Fosså A, Lilleby W, Fosså SD, Gaudernack G, Torlakovic G, Berner A (2002)
    Independent prognostic significance of HER-2 oncoprotein expression in pN0 prostate cancer undergoing curative radiotherapy
    Int J Cancer, 99 (1), 100-5
    PubMed 11948499
  5. Paulsen JE, Bjørheim J, Røe J, Eide TJ, Alexander J, Gaudernack G (2002)
    Effect of vaccination with mutant KRAS peptides on rat colon carcinogenesis induced by azoxymethane
    Anticancer Res, 22 (1A), 171-5
    PubMed 12017282
  6. Saebøe-Larssen S, Fossberg E, Gaudernack G (2002)
    mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT)
    J Immunol Methods, 259 (1-2), 191-203
    PubMed 11730854

Publications 2001

  1. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT et al. (2001)
    Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study
    Br J Cancer, 85 (5), 692-6
    PubMed 11531254
  2. Bjørheim J, Ekstrøm PO, Fossberg E, Børresen-Dale AL, Gaudernack G (2001)
    Automated constant denaturant capillary electrophoresis applied for detection of KRAS exon 1 mutations
    Biotechniques, 30 (5), 972-5
    PubMed 11355359
  3. Bjørheim J, Gaudernack G, Ekstrøm PO (2001)
    Mutation analysis of TP53 exons 5-8 by automated constant denaturant capillary electrophoresis
    Tumour Biol, 22 (5), 323-7
    PubMed 11553863
  4. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Søreide O, Eriksen JA, Møller M, Baksaas I, Lothe RA, Saeterdal I, Gaudernack G (2001)
    Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma
    Int J Cancer, 92 (3), 441-50
    PubMed 11291084
  5. Hunger RE, Brand CU, Streit M, Eriksen JA, Gjertsen MK, Saeterdal I, Braathen LR, Gaudernack G (2001)
    Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant
    Exp Dermatol, 10 (3), 161-7
    PubMed 11380611
  6. Saeterdal I, Bjørheim J, Lislerud K, Gjertsen MK, Bukholm IK, Olsen OC, Nesland JM, Eriksen JA, Møller M, Lindblom A, Gaudernack G (2001)
    Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer
    Proc Natl Acad Sci U S A, 98 (23), 13255-60
    PubMed 11687624
  7. Saeterdal I, Gjertsen MK, Straten P, Eriksen JA, Gaudernack G (2001)
    A TGF betaRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8+ T cells
    Cancer Immunol Immunother, 50 (9), 469-76
    PubMed 11761441

Publications 2000

  1. Fosså A, Siebert R, Aasheim HC, Maelandsmo GM, Berner A, Fosså SD, Paus E, Smeland EB, Gaudernack G (2000)
    Identification of nucleolar protein No55 as a tumour-associated autoantigen in patients with prostate cancer
    Br J Cancer, 83 (6), 743-9
    PubMed 10952778

Publications 1999

  1. Baekkevold ES, Jahnsen FL, Johansen FE, Bakke O, Gaudernack G, Brandtzaeg P, Haraldsen G (1999)
    Culture characterization of differentiated high endothelial venule cells from human tonsils
    Lab Invest, 79 (3), 327-36
    PubMed 10092069
  2. Berg K, Selbo PK, Prasmickaite L, Tjelle TE, Sandvig K, Moan J, Gaudernack G, Fodstad O, Kjølsrud S, Anholt H, Rodal GH, Rodal SK, Høgset A (1999)
    Photochemical internalization: a novel technology for delivery of macromolecules into cytosol
    Cancer Res, 59 (6), 1180-3
    PubMed 10096543
  3. Breivik J, Gaudernack G (1999)
    Carcinogenesis and natural selection: a new perspective to the genetics and epigenetics of colorectal cancer
    Adv Cancer Res, 76, 187-212
    PubMed 10218102
  4. Breivik J, Gaudernack G (1999)
    Genomic instability, DNA methylation, and natural selection in colorectal carcinogenesis
    Semin Cancer Biol, 9 (4), 245-54
    PubMed 10448112
  5. Gaudernack G, Gjertsen MK (1999)
    Combination of GM-CSF with antitumour vaccine strategies
    Eur J Cancer, 35 Suppl 3, S33-5
    PubMed 10645220

Publications 1998

  1. Bjørheim J, Lystad S, Lindblom A, Kressner U, Westring S, Wahlberg S, Lindmark G, Gaudernack G, Ekstrøm P, Røe J, Thilly WG, Børresen-Dale AL (1998)
    Mutation analyses of KRAS exon 1 comparing three different techniques: temporal temperature gradient electrophoresis, constant denaturant capillary electrophoresis and allele specific polymerase chain reaction
    Mutat Res, 403 (1-2), 103-12
    PubMed 9726011
  2. Gjertsen MK, Bakka A, Buanes T, Rosseland A, Quist HL, Faerden A, Eriksen JA, Moller M, Baksaas I, Soreide O, Giercksky KE, Gaudernack G (1998)
    Intradermal ras peptide vaccines with GM-CSF as adjuvant
    17TH INTERNATIONAL CANCER CONGRESS, VOL 1 AND 2, 149-152
  3. Gjertsen MK, Gaudernack G (1998)
    Mutated Ras peptides as vaccines in immunotherapy of cancer
    Vox Sang, 74 Suppl 2, 489-95
    PubMed 9704487
  4. Pettersen RD, Gaudernack G, Olafsen MK, Lie SO, Hestdal K (1998)
    The TCR-binding region of the HLA class I alpha2 domain signals rapid Fas-independent cell death: a direct pathway for T cell-mediated killing of target cells?
    J Immunol, 160 (9), 4343-52
    PubMed 9574538
  5. Saeterdal I, thor Straten P, Myklebust JH, Kirkin AF, Gjertsen MK, Gaudernack G (1998)
    Generation and characterization of gp100 peptide-specific NK-T cell clones
    Int J Cancer, 75 (5), 794-803
    PubMed 9495251

Publications 1997

  1. Andersen SN, Løvig T, Breivik J, Lund E, Gaudernack G, Meling GI, Rognum TO (1997)
    K-ras mutations and prognosis in large-bowel carcinomas
    Scand J Gastroenterol, 32 (1), 62-9
    PubMed 9018769
  2. Breivik J, Lothe RA, Meling GI, Rognum TO, Børresen-Dale AL, Gaudernack G (1997)
    Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors
    Int J Cancer, 74 (6), 664-9
    PubMed 9421366
  3. Gaudernack G (1997)
    Ras peptide vaccines
    SYMPOSIUM IN IMMUNOLOGY VI: TUMOR IMMUNOLOGY, 137-146
  4. Gjertsen MK, Bjorheim J, Saeterdal I, Myklebust J, Gaudernack G (1997)
    Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation
    Int J Cancer, 72 (5), 784-90
    PubMed 9311595
  5. Rasmussen AM, Horejsí V, Levy FO, Blomhoff HK, Smeland EB, Beiske K, Michaelsen TE, Gaudernack G, Funderud S (1997)
    CDw78--a determinant on a major histocompatibility complex class II subpopulation that can be induced to associate with the cytoskeleton
    Eur J Immunol, 27 (12), 3206-13
    PubMed 9464807

Publications 1996

  1. Andersen SN, Breivik J, Lovig T, Meling GI, Gaudernack G, Clausen OPF, Schjolberg A, Fausa O, Langmark F, Lund E, Rognum TO (1996)
    K-ras mutations and HLA-DR expression in large bowel adenomas
    Br. J. Cancer, 74 (1), 99-108
  2. Donahue RE, Byrne ER, Thomas TE, Kirby MR, Agricola BA, Sellers SE, Gaudernack G, Karisson S, Lansdorp PM (1996)
    Transplantation and gene transfer of the human glucocerebrosidase gene into immunoselected primate CD34+Thy-1+ cells
    Blood, 88 (11), 4166-72
    PubMed 8943851
  3. Gaudernack G (1996)
    T cell responses against mutant ras: a basis for novel cancer vaccines
    Immunotechnology, 2 (1), 3-9
    PubMed 9373323
  4. Gjersten MK, Saeterdal I, Beiske K, Gaudernack G (1996)
    Antigen-presenting function of human peritoneum mesothelial cells isolated from a pancreatic carcinoma patient after mutant Ras peptide vaccination
    Cancer Immunol Immunother, 43 (5), 262-8
    PubMed 9024502
  5. Gjertsen M, Bakka A, Soreide O, Thorsby E, Gaudernack G (1996)
    Ras peptide vaccination in patients with advanced pancreatic cancer: Results of a phase I/II study
    2ND WORLD CONGRESS - INTERNATIONAL HEPATO-PANCREATO-BILIARY ASSOCIATION, VOL II: BILIARY-PANCREAS, 1121-1125
  6. Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Gedde-Dahl T, Stokke KT, Sølheim BG, Egge TS, Søreide O, Thorsby E, Gaudernack G (1996)
    Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study
    Int J Cancer, 65 (4), 450-3
    PubMed 8621226
  7. Gjertsen MK, Saeterdal I, Thorsby E, Gaudernack G (1996)
    Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination
    Br J Cancer, 74 (11), 1828-33
    PubMed 8956801
  8. Norheim Andersen S, Breivik J, Løvig T, Meling GI, Gaudernack G, Clausen OP, Schjölberg A, Fausa O, Langmark F, Lund E, Rognum TO (1996)
    K-ras mutations and HLA-DR expression in large bowel adenomas
    Br J Cancer, 74 (1), 99-108
    PubMed 8679466
  9. Pettersen RD, Hestdal K, Lie SO, Gaudernack G (1996)
    Role of the TCR binding region of the HLA class I alpha 2 domain in regulation of cell adhesion and proliferation
    J Immunol, 156 (4), 1415-24
    PubMed 8568242
  10. Steen R, Tjønnfjord GE, Gaudernack G, Brinch L, Egeland T (1996)
    Differences in the distribution of CD34 epitopes on normal haemopoietic progenitor cells and leukaemic blast cells
    Br J Haematol, 94 (4), 597-605
    PubMed 8826880

Publications 1995

  1. Fossum B, Olsen AC, Thorsby E, Gaudernack G (1995)
    CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (Gly13-->Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation
    Cancer Immunol Immunother, 40 (3), 165-72
    PubMed 7728775
  2. Gjertsen MK, Bakka A, Breivik J, Saeterdal I, Solheim BG, Søreide O, Thorsby E, Gaudernack G (1995)
    Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation
    Lancet, 346 (8987), 1399-400
    PubMed 7475823
  3. Olsen AC, Fossum B, Kirkin AF, Zeuthen J, Gaudernack G (1995)
    A human melanoma cell line, recognized by both HLA class I and class II restricted T cells, is capable of initiating both primary and secondary immune responses
    Scand J Immunol, 41 (4), 357-64
    PubMed 7899823
  4. Pettersen RD, Hestdal K, Lee N, Geraghty DE, Valø ET, Lie SO, Gaudernack G (1995)
    RG1, a new murine monoclonal antibody recognizing a "supertypic" determinant on HLA-A molecules
    Tissue Antigens, 45 (3), 203-12
    PubMed 7539160
  5. Puri KD, Finger EB, Gaudernack G, Springer TA (1995)
    Sialomucin CD34 is the major L-selectin ligand in human tonsil high endothelial venules
    J Cell Biol, 131 (1), 261-70
    PubMed 7559783
  6. Viken HD, Paulsen G, Drover S, Marshall WH, Sollid LM, Gaudernack G, Thorsby E (1995)
    Influence on antibody recognition of amino acid substitutions in the cleft of HLA-DQ2 molecules. Suggestive evidence of peptide-dependent epitopes
    Hum Immunol, 44 (2), 63-9
    PubMed 8847230
  7. Viken HD, Paulsen G, Sollid LM, Lundin KE, Tjønnfjord GE, Thorsby E, Gaudernack G (1995)
    Characterization of an HLA-DQ2-specific monoclonal antibody. Influence of amino acid substitutions in DQ beta 1*0202
    Hum Immunol, 42 (4), 319-27
    PubMed 7558917
  8. Viken HD, Thorsby E, Gaudernack G (1995)
    Characterization and epitope mapping of four HLA class II reactive mouse monoclonal antibodies using transfected L cells and human cells transfected with mutants of DQB1*0302
    Tissue Antigens, 45 (4), 250-7
    PubMed 7638861

Publications 1994

  1. Breivik J, Meling GI, Spurkland A, Rognum TO, Gaudernack G (1994)
    K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location
    Br J Cancer, 69 (2), 367-71
    PubMed 8297737
  2. EGELAND T, GAUDERNACK G (1994)
    IMMUNOMAGNETIC ISOLATION OF CD34+ CELLS - METHODOLOGY AND MONOCLONAL ANTIBODIES
    HEMATOPOIETIC STEM CELLS: THE MULHOUSE MANUAL, 141-148
  3. Fossum B, Breivik J, Meling GI, Gedde-Dahl T, Hansen T, Knutsen I, Rognum TO, Thorsby E, Gaudernack G (1994)
    A K-ras 13Gly-->Asp mutation is recognized by HLA-DQ7 restricted T cells in a patient with colorectal cancer. Modifying effect of DQ7 on established cancers harbouring this mutation?
    Int J Cancer, 58 (4), 506-11
    PubMed 7914513
  4. Fossum B, Gedde-Dahl T, Breivik J, Eriksen JA, Spurkland A, Thorsby E, Gaudernack G (1994)
    p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly-->Asp)
    Int J Cancer, 56 (1), 40-5
    PubMed 7903287
  5. Gedde-Dahl T, Nilsen E, Thorsby E, Gaudernack G (1994)
    Growth inhibition of a colonic adenocarcinoma cell line (HT29) by T cells specific for mutant p21 ras
    Cancer Immunol Immunother, 38 (2), 127-34
    PubMed 8306368
  6. Gedde-Dahl T, Spurkland A, Fossum B, Wittinghofer A, Thorsby E, Gaudernack G (1994)
    T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA
    Eur J Immunol, 24 (2), 410-4
    PubMed 7507844
  7. Ghaderi AA, Gaudernack G, Stanworth DR (1994)
    Cross-linking of a sequential epitope within the beta-chain of HLA-DR/DP molecules suppressing B lymphocyte growth and inducing homotypic cell aggregation
    Immunol Lett, 39 (2), 113-9
    PubMed 7516911
  8. Gjertsen HA, Fossum B, Hansen T, Lundin KE, Gaudernack G, Thorsby E (1994)
    HLA restriction fine-specificity and T-cell receptor usage of T cells recognizing DQ7
    Tissue Antigens, 43 (4), 266-70
    PubMed 8085264
  9. Johansen BH, Gedde-Dahl T, Sollid LM, Vartdal F, Thorsby E, Gaudernack G (1994)
    Binding of ras oncogene peptides to purified HLA-DQ (alpha 1*0102, beta 1*0602) and -DR (alpha, beta 1*0101) molecules
    Scand J Immunol, 40 (4), 468
    PubMed 7939420
  10. Johansen BH, Gedde-Dahl T, Sollid LM, Vartdal F, Thorsby E, Gaudernack G (1994)
    Binding of ras oncogene peptides to purified HLA-DQ(alpha 1*0102,beta 1*0602) and -DR(alpha,beta 1*0101) molecules
    Scand J Immunol, 39 (6), 607-12
    PubMed 8009176
  11. Spurkland A, Gedde-Dahl T, Hansen T, Vartdal F, Gaudernack G, Thorsby E (1994)
    Heterogeneity of T cells specific for a particular peptide/HLA-DQ complex
    Hum Immunol, 39 (1), 61-8
    PubMed 8181964

Publications 1993

  1. Egeland T, Tjønnfjord G, Steen R, Gaudernack G, Thorsby E (1993)
    Positive selection of bone marrow-derived CD34 positive cells for possible stem cell transplantation
    Transplant Proc, 25 (1 Pt 2), 1261-3
    PubMed 7680152
  2. Fossum B, Gedde-Dahl T, Hansen T, Eriksen JA, Thorsby E, Gaudernack G (1993)
    Overlapping epitopes encompassing a point mutation (12 Gly-->Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells
    Eur J Immunol, 23 (10), 2687-91
    PubMed 7691613
  3. Gedde-Dahl T, Fossum B, Eriksen JA, Thorsby E, Gaudernack G (1993)
    T cell clones specific for p21 ras-derived peptides: characterization of their fine specificity and HLA restriction
    Eur J Immunol, 23 (3), 754-60
    PubMed 8449222
  4. Gedde-Dahl T, Olsen BH, Thorsby E, Gaudernack G (1993)
    Oncogene-derived peptides: a new class of tumor rejection antigens?
    Transplant Proc, 25 (1 Pt 2), 1385-6
    PubMed 8442151

Publications 1992

  1. Brinchmann JE, Gaudernack G, Thorsby E, Vartdal F (1992)
    Staphylococcal exotoxin superantigens induce human immunodeficiency virus type 1 expression in naturally infected CD4+ T cells
    J Virol, 66 (10), 5924-8
    PubMed 1356159
  2. EGELAND T, QUARSTEN H, GAUDERNACK G (1992)
    EFFECT OF RECOMBINANT STEM-CELL GROWTH-FACTORS ON IMMUNOMAGNETICALLY ISOLATED CD34+ CELLS
    INT J CELL CLONING, 10 1, 53-55
  3. Gedde-Dahl T, Eriksen JA, Thorsby E, Gaudernack G (1992)
    T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides
    Hum Immunol, 33 (4), 266-74
    PubMed 1639630
  4. Gedde-Dahl T, Spurkland A, Eriksen JA, Thorsby E, Gaudernack G (1992)
    Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-->Leu61)
    Int Immunol, 4 (11), 1331-7
    PubMed 1282032
  5. Onsrud M, Grahm I, Gaudernack G, Tropé C (1992)
    Lymphoid cell distribution as prognostic factor in carcinoma of the uterine cervix
    Acta Obstet Gynecol Scand, 71 (2), 135-9
    PubMed 1316042
  6. Pettersen KS, Wiiger MT, Narahara N, Andoh K, Gaudernack G, Prydz H (1992)
    Induction of tissue factor synthesis in human umbilical vein endothelial cells involves protein kinase C
    Thromb Haemost, 67 (4), 473-7
    PubMed 1631796
  7. Smeland EB, Funderud S, Kvalheim G, Gaudernack G, Rasmussen AM, Rusten L, Wang MY, Tindle RW, Blomhoff HK, Egeland T (1992)
    Isolation and characterization of human hematopoietic progenitor cells: an effective method for positive selection of CD34+ cells
    Leukemia, 6 (8), 845-52
    PubMed 1379314

Publications 1991

  1. Brinchmann JE, Gaudernack G, Vartdal F (1991)
    In vitro replication of HIV-1 in naturally infected CD4+ T cells is inhibited by rIFN alpha 2 and by a soluble factor secreted by activated CD8+ T cells, but not by rIFN beta, rIFN gamma, or recombinant tumor necrosis factor-alpha
    J Acquir Immune Defic Syndr, 4 (5), 480-8
    PubMed 1673156
  2. Egeland T, Steen R, Quarsten H, Gaudernack G, Yang YC, Thorsby E (1991)
    Myeloid differentiation of purified CD34+ cells after stimulation with recombinant human granulocyte-monocyte colony-stimulating factor (CSF), granulocyte-CSF, monocyte-CSF, and interleukin-3
    Blood, 78 (12), 3192-9
    PubMed 1720697
  3. Gjertsen HA, Lundin KE, Rønningen KS, Gaudernack G, Thorsby E (1991)
    T cells recognizing an HLA-DQ alpha beta heterodimer encoded in cis by the DR4DQw4 haplotype and in trans by DR4DQw8/DRw8DQw4 heterozygous cells
    Hum Immunol, 30 (3), 226-32
    PubMed 2055788

Publications 1990

  1. Brinchmann JE, Gaudernack G, Vartdal F (1990)
    CD8+ T cells inhibit HIV replication in naturally infected CD4+ T cells. Evidence for a soluble inhibitor
    J Immunol, 144 (8), 2961-6
    PubMed 1969879
  2. Brun A, Gaudernack G, Sandberg S (1990)
    A new method for isolation of reticulocytes: positive selection of human reticulocytes by immunomagnetic separation
    Blood, 76 (11), 2397-403
    PubMed 2257309
  3. Lundin KE, Sollid LM, Bosnes V, Gaudernack G, Thorsby E (1990)
    T-cell recognition of HLA class II molecules induced by gamma-interferon on a colonic adenocarcinoma cell line (HT29)
    Scand J Immunol, 31 (4), 469-75
    PubMed 2110380
  4. Molloy A, Gaudernack G, Levis WR, Cohn ZA, Kaplan G (1990)
    Suppression of T-cell proliferation by Mycobacterium leprae and its products: the role of lipopolysaccharide
    Proc Natl Acad Sci U S A, 87 (3), 973-7
    PubMed 1689064
  5. Müller F, Rollag H, Gaudernack G, Frøland SS (1990)
    Impaired in vitro survival of monocytes from patients with HIV infection
    Clin Exp Immunol, 81 (1), 25-30
    PubMed 1974179
  6. Skjønsberg C, Kiil Blomhoff H, Gaudernack G, Funderud S, Beiske K, Smeland EB (1990)
    Immunological typing of acute leukaemias by rosetting with immunomagnetic beads: comparison with immunofluorescence staining
    Scand J Immunol, 31 (5), 567-73
    PubMed 2189214

Publications 1989

  1. Bosnes V, Halvorsen R, Gaudernack G, Thorsby E (1989)
    Isolation of functionally active T cell receptor gamma delta-bearing lymphocytes from human peripheral blood
    J Immunol Methods, 118 (2), 251-5
    PubMed 2466905
  2. Bosnes V, Halvorsen R, Skaftadottir I, Gaudernack G, Thorsby E (1989)
    Specificity of gamma delta receptor-bearing cytotoxic T lymphocytes isolated from human peripheral blood
    Scand J Immunol, 29 (6), 723-31
    PubMed 2525809
  3. Brinchmann JE, Gaudernack G, Thorsby E, Jonassen TO, Vartdal F (1989)
    Reliable isolation of human immunodeficiency virus from cultures of naturally infected CD4+ T cells
    J Virol Methods, 25 (3), 293-300
    PubMed 2573612
  4. Carlsen E, Gaudernack G, Filion-Myklebust C, Pettersen KS, Prydz H (1989)
    Allogenic induction of thromboplastin synthesis in monocytes and endothelial cells. Biphasic effect of cyclosporin A
    Clin Exp Immunol, 76 (3), 428-33
    PubMed 2526700
  5. CARLSEN E, GAUDERNACK G, FILIONMYKLEBUST C, PETTERSEN KS, PRYDZ H (1989)
    ALLOGENEIC INDUCTION OF THROMBOPLASTIN SYNTHESIS IN MONOCYTES AND ENDOTHELIAL-CELLS - BIPHASIC EFFECT OF CYCLOSPORINE-A
    Clin. Exp. Immunol., 76 (3), 428-433
  6. Gaudernack G, Lundin KE (1989)
    Rapid immunomagnetic phenotyping of cells
    J Immunogenet, 16 (2), 169-75
    PubMed 2687387
  7. Holte H, Blomhoff HK, Beiske K, Funderud S, Torjesen P, Gaudernack G, Stokke T, Smeland EB (1989)
    Intracellular events associated with inhibition of B cell activation by monoclonal antibodies to HLA class II antigens
    Eur J Immunol, 19 (7), 1221-5
    PubMed 2547623
  8. Hovdenes J, Gaudernack G, Kvien TK, Egeland T (1989)
    Expression of activation markers on CD4+ and CD8+ cells from synovial fluid, synovial tissue, and peripheral blood of patients with inflammatory arthritides
    Scand J Immunol, 29 (6), 631-9
    PubMed 2544985
  9. Hovdenes J, Gaudernack G, Kvien TK, Egeland T, Mellbye OJ (1989)
    A functional study of purified CD4+ and CD8+ cells isolated from synovial fluid of patients with rheumatoid arthritis and other arthritides
    Scand J Immunol, 29 (6), 641-9
    PubMed 2500703
  10. Hovdenes J, Gaudernack G, Kvien TK, Hovdenes AB, Egeland T (1989)
    Mitogen-induced interleukin 2 and gamma interferon production by CD4+ and CD8+ cells of patients with inflammatory arthritides. A comparison between cells from synovial fluid and peripheral blood
    Scand J Immunol, 30 (5), 597-603
    PubMed 2511620
  11. Leivestad T, Halvorsen R, Gaudernack G, Thorsby E (1989)
    Ability of pure resting CD8+ human T cells to respond to alloantigen
    Scand J Immunol, 29 (5), 543-53
    PubMed 2524873
  12. Lundin KE, Bosnes V, Gaudernack G (1989)
    Human T lymphocyte clones: influence of culture conditions and optimization of proliferative assays
    Scand J Immunol, 30 (1), 83-9
    PubMed 2787928
  13. Lundin KE, Ovigstad E, Sollid LM, Gjertsen HA, Gaudernack G, Thorsby E (1989)
    Positive selection of Tac- (CD25) positive cells following T-cell activation. Use of immunomagnetic separation and implications for T-cell cloning
    J Immunogenet, 16 (2), 185-91
    PubMed 2687389
  14. Lundin KE, Rønningen KS, Aono S, Spurkland A, Gaudernack G, Isshiki G, Thorsby E (1989)
    HLA-DQ antigens and DQ beta amino acid 57 of Japanese patients with insulin-dependent diabetes mellitus: detection of a DRw8DQw8 haplotype
    Tissue Antigens, 34 (4), 233-41
    PubMed 2617513
  15. LUNDIN KEA, BOSNES V, GAUDERNACK G (1989)
    HUMAN LYMPHOCYTE-T CLONES - INFLUENCE OF CULTURE CONDITIONS AND OPTIMIZATION OF PROLIFERATIVE ASSAYS
    Scand. J. Immunol., 30 (1), 83-89
  16. Pfeffer PF, Gjertsen HA, Gaudernack G, Lexow PB, Sodal G, Thorsby E (1989)
    Analysis of infiltrating lymphocytes from fine needle aspiration biopsies in kidney transplant patients by a rapid and sensitive immunomagnetic method
    Transplant Proc, 21 (1 Pt 1), 354-5
    PubMed 2495609
  17. Solum NO, Aakhus AM, Pedersen T, Gaudernack G (1989)
    The PhastSystem equipment used for crossed immunoelectrophoresis combined with immunoblotting of coprecipitated monoclonal antibodies as studied with platelet membrane receptor proteins
    Electrophoresis, 10 (11), 752-8
    PubMed 2612475
  18. Viken HD, Gaudernack G, Thorsby E (1989)
    Characterization of a monoclonal antibody recognizing a polymorphic epitope mainly on HLA-DPw2 and DPw4 molecules
    Tissue Antigens, 34 (4), 250-9
    PubMed 2482551

Publications 1988

  1. Brinchmann JE, Vartdal F, Gaudernack G, Markussen G, Funderud S, Ugelstad J, Thorsby E (1988)
    Direct immunomagnetic quantification of lymphocyte subsets in blood
    Clin Exp Immunol, 71 (1), 182-6
    PubMed 3349645
  2. Halvorsen R, Leivestad T, Gaudernack G, Thorsby E (1988)
    Role of accessory cells in the activation of pure T cells via the T cell receptor-CD3 complex or with phytohaemagglutinin
    Scand J Immunol, 27 (5), 555-63
    PubMed 2967540
  3. Halvorsen R, Leivestad T, Gaudernack G, Thorsby E (1988)
    Accessory cell-dependent T-cell activation via Ti-CD3. Involvement of CD2-LFA-3 interactions
    Scand J Immunol, 28 (3), 277-84
    PubMed 2461580
  4. Halvorsen R, Leivestad T, Gaudernack G, Thorsby E (1988)
    Induction of interleukin-2 production in CD4+ and CD8+ T-cell subsets after activation via CD3 and CD2
    Scand J Immunol, 28 (4), 449-55
    PubMed 2904172
  5. Helgestad J, Bøyum A, Storm-Mathisen I, Gaudernack G, Lie SO (1988)
    Human granulopoiesis in vitro--medium-dependent growth regulation by a granulocyte-derived inhibitor
    Acta Physiol Scand, 133 (1), 41-7
    PubMed 3265841
  6. Johne B, Bryn K, Gaudernack G, Myhrvold V, Morland B (1988)
    Activation of mononuclear phagocyte functions by structurally different bacterial endotoxins
    Adv Exp Med Biol, 237, 783-7
    PubMed 3075875
  7. Kvalheim G, Funderud S, Kvaløy S, Gaudernack G, Beiske K, Jakobsen E, Jacobsen AB, Pihl A, Fodstad O (1988)
    Successful clinical use of an anti-HLA-DR monoclonal antibody for autologous bone marrow transplantation
    J Natl Cancer Inst, 80 (16), 1322-5
    PubMed 3050139
  8. Leivestad T, Gaudernack G, Halvorsen R, Thorsby E (1988)
    A simple and sensitive bioassay for the detection of IL-2 activity
    J Immunol Methods, 114 (1-2), 95-9
    PubMed 2972783
  9. Leivestad T, Halvorsen R, Gaudernack G, Thorsby E (1988)
    Requirements for phytohaemagglutinin activation of resting pure CD4+ and CD8+ T cells
    Scand J Immunol, 27 (5), 565-72
    PubMed 3131868
  10. Lie O, Vartdal F, Funderud S, Gaudernack G, Olsaker I, Frøysadal E, Ugelstad J, Thorsby E (1988)
    Immunomagnetic isolation of cells for serological BoLA typing
    Anim Genet, 19 (2), 75-86
    PubMed 3137848
  11. Lundin KE, Gaudernack G, Qvigstad E, Sollid LM, Thorsby E (1988)
    T lymphocyte clones recognizing an HLA-DQw3.2-associated epitope involving residue 57 on the DQ beta chain
    Hum Immunol, 22 (4), 235-46
    PubMed 2459088
  12. LUNDIN KEA, GAUDERNACK G, QVIGSTAD E, SOLLID LM, THORSBY E (1988)
    LYMPHOCYTE-T CLONES RECOGNIZING AN HLA-DQW3.2-ASSOCIATED EPITOPE INVOLVING RESIDUE 57 ON THE DQ BETA-CHAIN
    Hum. Immunol., 22 (4), 235-246
  13. Markussen G, Rønningen KS, Paulsen G, Gaudernack G, Sollid LM, Thorsby E (1988)
    HLA-DQw3.1 and DQw3.2 associated exon polymorphisms detected by oligonucleotide probes
    Tissue Antigens, 31 (4), 204-10
    PubMed 3406934
  14. Sollid LM, Brandtzaeg P, Kvale D, Gaudernack G, Scott H, Thorsby E (1988)
    T cell-epithelium interactions in relation to gut immunity
    Monogr Allergy, 24, 60-5
    PubMed 3129651
  15. Tanum G, Gaudernack G (1988)
    Small megakaryocytes--an identification problem
    Res Exp Med (Berl), 188 (2), 95-9
    PubMed 2453905
  16. Thorsen LI, Gaudernack G, Hack N, Wilkinson JM, Brosstad F, Solum NO, Crawford N (1988)
    Characterization of a monoclonal antibody ITI-Pl 1 directed against human platelet membrane glycoprotein IIb using extracts of whole platelets and platelet surface and intracellular membranes
    Br J Haematol, 68 (1), 67-74
    PubMed 3278733

Publications 1987

  1. Halvorsen R, Gaudernack G, Leivestad T, Vartdal F, Thorsby E (1987)
    Activation of resting, pure CD4+, and CD8+ cells via CD3. Requirements for second signals
    Scand J Immunol, 26 (2), 197-205
    PubMed 2957786
  2. Johne B, Gaudernack G, Mørland B (1987)
    Effects of endotoxins from Bacteroides intermedius and Escherichia coli on human monocytes in vitro
    Acta Pathol Microbiol Immunol Scand C, 95 (6), 241-50
    PubMed 2964769
  3. Leivestad T, Gaudernack G, Ugelstad J, Vartdal F, Thorsby E (1987)
    Isolation of pure and functionally active T4 and T8 cells by positive selection with antibody-coated monosized magnetic microspheres
    Transplant Proc, 19 (1 Pt 1), 265-7
    PubMed 3152700
  4. Mørk NJ, Gaudernack G, Braathen LR (1987)
    Effect of UVA and PUVA on alloactivating and antigen-presenting capacity of human epidermal Langerhans cells
    Photodermatol, 4 (2), 66-72
    PubMed 3498937
  5. Sollid L, Paulsen G, Gaudernack G, Thorsby E (1987)
    HLA class II profile of a human carcinoma cell line: detection on genomic level and after exposure to gamma-interferon
    Transplant Proc, 19 (1 Pt 1), 215
    PubMed 3152692
  6. Sollid LM, Gaudernack G, Markussen G, Kvale D, Brandtzaeg P, Thorsby E (1987)
    Induction of various HLA class II molecules in a human colonic adenocarcinoma cell line
    Scand J Immunol, 25 (2), 175-80
    PubMed 2434988
  7. Thorsen LI, Gaudernack G, Brosstad F, Pedersen TM, Solum NO (1987)
    Identification of platelet antigens by monoclonal antibodies using crossed immunoelectrophoresis with immunoblotting of the monoclonal antibody
    Thromb Haemost, 57 (2), 212-6
    PubMed 3299855
  8. VARTDAL F, ALBRECHTSEN D, RINGDEN O, KVALHEIM G, LEA T, BOSNES V, GAUDERNACK G, BRINCHMANN J, UGELSTAD J (1987)
    IMMUNOMAGNETIC TREATMENT OF BONE-MARROW ALLOGRAFTS
    Bone Marrow Transplant., 2 2, 94-98
  9. Vartdal F, Bratlie A, Gaudernack G, Funderud S, Lea T, Thorsby E (1987)
    Microcytotoxic HLA typing of cells directly isolated from blood by means of antibody-coated microspheres
    Transplant Proc, 19 (1 Pt 1), 655-7
    PubMed 3152705
  10. Vartdal F, Kvalheim G, Lea TE, Bosnes V, Gaudernack G, Ugelstad J, Albrechtsen D (1987)
    Depletion of T lymphocytes from human bone marrow. Use of magnetic monosized polymer microspheres coated with T-lymphocyte-specific monoclonal antibodies
    Transplantation, 43 (3), 366-71
    PubMed 3103274

Publications 1986

  1. Bjercke S, Onsrud M, Gaudernack G (1986)
    Suppressive effect of monocytes in vitro in patients with carcinoma of the uterine cervix
    Acta Obstet Gynecol Scand, 65 (6), 619-24
    PubMed 3026137
  2. Bruserud O, Sollid L, Gaudernack G, Thorsby E (1986)
    The role of the CD8-positive subset of T cells in proliferative responses to soluble antigens. II. CD8-positive cells are not responsible for DR-associated differences in responsiveness to mumps and Coxsackie B4
    Scand J Immunol, 23 (4), 469-73
    PubMed 3010444
  3. Gaudernack G, Leivestad T, Ugelstad J, Thorsby E (1986)
    Isolation of pure functionally active CD8+ T cells. Positive selection with monoclonal antibodies directly conjugated to monosized magnetic microspheres
    J Immunol Methods, 90 (2), 179-87
    PubMed 3088118
  4. LEIVESTAD T, GAUDERNACK G, QVIGSTAD E, UGELSTAD J, THORSBY E (1986)
    ISOLATION OF FUNCTIONALLY ACTIVE T-CELL SUBSETS BY MONOCLONAL-ANTIBODIES CONJUGATED TO MONODISPERSE MAGNETIC MICROSPHERES (M-450)
    Transplant. Proc., 18 (4), 731-732
  5. Leivestad T, Gaudernack G, Ugelstad J, Thorsby E (1986)
    Positive selection of activated T cells of the T8 (CD8) sub-type by immunomagnetic separation
    Tissue Antigens, 28 (1), 46-52
    PubMed 3018960
  6. Onsrud M, Grahm I, Gaudernack G (1986)
    Early stage carcinoma of the uterine cervix. Effects of intracavitary radium treatment on lymphoid cells in blood and pelvic lymph nodes
    Acta Radiol Oncol, 25 (2), 127-30
    PubMed 3012956
  7. Sollid L, Bruserud O, Gaudernack G, Thorsby E (1986)
    The role of the CD8-positive subset of T cells in proliferative responses to soluble antigens. I. Studies of healthy subjects, type 1 diabetics, and coeliac disease patients
    Scand J Immunol, 23 (4), 461-7
    PubMed 3010443
  8. Vartdal F, Gaudernack G, Funderud S, Bratlie A, Lea T, Ugelstad J, Thorsby E (1986)
    HLA class I and II typing using cells positively selected from blood by immunomagnetic isolation--a fast and reliable technique
    Tissue Antigens, 28 (5), 301-12
    PubMed 3469787

Publications 1985

  1. Andersen OK, Osterud B, Gaudernack G, Lundgren TI, Giercksky KE (1985)
    Tissue thromboplastin generation in circulating mononuclear phagocytes and development of coagulation disorders during E. coli endotoxinaemia in pigs
    Acta Chir Scand, 151 (3), 205-11
    PubMed 3925666
  2. Bjercke S, Braathen L, Gaudernack G, Thorsby E (1985)
    Relative efficiency of human Langerhans' cells and blood derived dendritic cells as antigen-presenting cells
    Acta Derm Venereol, 65 (5), 374-8
    PubMed 2416158
  3. Bjercke S, Gaudernack G (1985)
    Dendritic cells and monocytes as accessory cells in T-cell responses in man. II. Function as antigen-presenting cells
    Scand J Immunol, 21 (5), 501-8
    PubMed 3873688
  4. Bjercke S, Gaudernack G, Braathen LR (1985)
    Enriched Langerhans cells express more HLA-DR determinants than blood-derived adherent cells (monocytes and dendritic cells)
    Scand J Immunol, 21 (5), 489-92
    PubMed 2408326
  5. Gaudernack G, Bjercke S (1985)
    Dendritic cells and monocytes as accessory cells in T-cell responses in man. I. Phenotypic analysis of dendritic cells and monocytes
    Scand J Immunol, 21 (5), 493-500
    PubMed 3923613
  6. GAUDERNACK G, BJERCKE S, THORSBY E (1985)
    EXPRESSION OF HLA CLASS-II MOLECULES ON HUMAN-MONOCYTES AND DENDRITIC CELLS
    Transplant. Proc., 17 (1), 961-962
  7. Hetland O, Brovold AB, Holme R, Gaudernack G, Prydz H (1985)
    Thromboplastin (tissue factor) in plasma membranes of human monocytes
    Biochem J, 228 (3), 735-43
    PubMed 4026807
  8. Paulsen G, Qvigstad E, Gaudernack G, Rask L, Winchester R, Thorsby E (1985)
    Identification, at the genomic level, of an HLA-DR restriction element for cloned antigen-specific T4 cells
    J Exp Med, 161 (6), 1569-74
    PubMed 2409204

Publications 1984

  1. Gaudernack G, Halvorsen O, Skorping A, Stokkan KA (1984)
    Humoral immunity and output of first-stage larvae of Elaphostrongylus rangiferi (Nematoda, Metastrongyloidea) by infected reindeer, Rangifer tarandus tarandus
    J Helminthol, 58 (1), 13-8
    PubMed 6371122
  2. Qvigstad E, Gaudernack G, Thorsby E (1984)
    Antigen-specific T cell clones restricted by DR, DRw53 (MT), or DP (SB) Class II HLA molecules. Inhibition studies with monoclonal HLA-specific antibodies
    Hum Immunol, 11 (4), 207-17
    PubMed 6210280

Publications 1983

  1. Gaudernack G, Olstad R (1983)
    Tumor--host interactions in vivo. II. Induction of NK-cell activity by intraperitoneal injection of murine sarcoma cells or tumor ascites fluid
    Scand J Immunol, 17 (3), 275-82
    PubMed 6828825
  2. Aarstad HJ, Gaudernack G, Seljelid R (1983)
    Stress causes reduced natural killer activity in mice
    Scand J Immunol, 18 (5), 461-4
    PubMed 6648369

Publications 1982

  1. Curry R, Thoen J, Shelborne C, Gaudernack G, Messner R (1982)
    Antibodies to and elevations of beta 2 microglobulin in the serum of ankylosing spondylitis patients
    Arthritis Rheum, 25 (4), 375-80
    PubMed 6176246
  2. Kaplan G, Gaudernack G (1982)
    In vitro differentiation of human monocytes. Differences in monocyte phenotypes induced by cultivation on glass or on collagen
    J Exp Med, 156 (4), 1101-14
    PubMed 6961188
  3. Marhaug G, Gaudernack G, Bogen B, Husby G (1982)
    Monoclonal hybridoma antibodies to human amyloid related protein SAA
    Clin Exp Immunol, 50 (2), 390-6
    PubMed 7151332
  4. Vercelotti G, Mullins W, Curry R, Gaudernack G, Moldow C, Messner RP (1982)
    A unique monoclonal antibody inhibits the second wave of platelet aggregation
    Clin Immunol Immunopathol, 23 (3), 691-7
    PubMed 6981480

Publications 1981

  1. Gaudernack G, Curry R, Messner R (1981)
    Rapid identification of human B-lymphocytes and monocytes with rhodamine-labeled Brucella melitensis
    J Immunol Methods, 43 (3), 251-9
    PubMed 6972976

Publications 1980

  1. Jørgensen T, Gaudernack G, Hannestad K (1980)
    Immunization with the light chain and the VL domain of the isologous myeloma protein 315 inhibits growth of mouse plasmacytoma MOPC315
    Scand J Immunol, 11 (1), 29-35
    PubMed 9537026
  2. Olstad R, Gaudernack G, Kaplan G, Seljelid R (1980)
    T- and B-cell-independent activation of syngeneic macrophages by murine sarcoma cells
    Cancer Res, 40 (6), 2054-60
    PubMed 6966185

Publications 1979

  1. Gaudernack G, Hannestad K (1979)
    The plasma cell differentiation antigen PC.1 is absent in CH3/Tif and present in C3H/HeJ
    Scand J Immunol, 9 (4), 373-9
    PubMed 87010

Publications 1977

  1. Hannestad K, Gaudernack G (1977)
    Ligand-induced redistribution and augmentation of surface-bound myeloma protein on MOPC 315 plasmacytoma cells
    Scand J Immunol, 6 (1-2), 59-76
    PubMed 403594
  2. Jorgensen T, Gaudernack G, Hannestad K (1977)
    Production of BALB/c anti-idiotypic antibodies against the BALB/c myeloma protein 315 does not require an intact ligand-binding site
    Scand J Immunol, 6 (4), 311-8
    PubMed 67635

Publications 1975

  1. Gaudernack G, Prydz H (1975)
    Studies on PIVKA-X
    Thromb Diath Haemorrh, 34 (2), 455-64
    PubMed 812196
  2. Kaplan G, Gaudernack G, Seljelid R (1975)
    Localization of receptors and early events of phagocytosis in the macrophage
    Exp Cell Res, 95 (2), 365-75
    PubMed 1193157

Publications 1974

  1. Gaudernack G, Berre AG, Osterud B, Prydz H (1974)
    Immunological studies on the blood coagulation Factor X and its warfarin-induced precursor
    Thromb Diath Haemorrh, 31 (1), 40-51
    PubMed 4209391

Publications 1973

  1. Gaudernack G, Rugstad HE, Hegna I, Prydz H (1973)
    Synthesis of serum proteins by a clonal strain of rat hepatoma cells
    Exp Cell Res, 77 (1), 25-30
    PubMed 4347806

Publications 1971

  1. Prydz H, Gaudernack G (1971)
    Studies on the biosynthesis of factor VII (proconvertin). The mode of action of warfarin
    Biochim Biophys Acta, 230 (2), 373-80
    PubMed 4324764
 
 
Feb 5, 2004 [11769 visits]
>> Go back   >> Print this page   >> E-mail this page